Innovation and therapeutic focus Novo Nordisk ® hlights first three months 2023 Further raise innovation bar for Diabetes treatment • Regulatory submission of once-weekly insulin icodec • Completion of phase 3 trial PIONEER PLUS • Completion of phase 1/2 trials with GLP-1/GIP Develop superior treatment solutions for obesity • Phase 3a trials REDEFINE 2 & 3 initiated with CagriSema Strengthen and progress Rare Disease pipeline • Somapacitan approved in the US for GHD in children • CRL received for concizumab in the US Establish presence in Other serious chronic diseases • Phase 1 trials initiated with cell therapy treatment Sales growth of 25% (CER) and operating profit growth of 28% (CER) Operational leverage reflecting sales growth Free cash flow of DKK 24.8 billion and DKK 23.5 billion returned to shareholders value market share iency; GIP: Gastric inhibitory polypeptide; GLP-1: Glucagon Like Peptide 1 Financials
Download PDF file